Newswise — NEW YORK, NY – August 21, 2015 – The Cardiovascular Research Foundation (CRF) has announced the late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific symposium. From an unprecedented number of high-quality submissions, TCT has chosen 20 studies that will impact the care of patients and how physicians think about cardiovascular disease. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 11-15, 2015 at the Moscone Center in San Francisco, California.
Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that are currently or soon to be available to patients. The studies selected will examine the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, the leading cause of death in the world. Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Monday, October 12; Tuesday, October 13; Wednesday, October 14; and Thursday, October 15.
The complete agenda for TCT 2015 is also available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty on the TCT Web site. Media are invited to attend TCT; press credentials and registration information can be found here: http://www.crf.org/tct/press/press-credentials-and-guidelines.
Monday, October 12•ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery DiseaseDean J. Kereiakes
•ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery DiseaseRun-Lin Gao
•A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and InterventionShigeru Saito
•ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease – Two-Year OutcomesBernard R. Chevalier
•BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold – Six-Month Clinical, Angiographic, and Imaging OutcomesMichael Haude
Tuesday, October 13•RIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary InterventionGiora Weisz
•EXPLORE: A Prospective Randomized Trial of Chronic Total Occlusion Intervention Versus Medical Therapy After Successful Primary Angioplasty in Patients With ST-Segment Elevation Myocardial InfarctionJose P.S. Henriques
•TOTAL: A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction – One-Year OutcomesSanjit S. Jolly
•A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom OnsetSteffen Desch
•PLATFORM: Quality-of-Life and Economic Outcomes of an FFR-CT Diagnostic Strategy in Patients With Suspected Coronary Artery DiseaseMark Andrew Hlatky
Wednesday, October 14•LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for BleedingPhilip M. Urban
•TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery DiseaseUpendra Kaul
•PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption KineticsXu Bo
•ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent RestenosisRobert A. Byrne
•IN.PACT SFA: A Prospective Randomized Trial of a Drug-Coated Balloon for Femoropopliteal Lesions – Two-Year OutcomesJohn R. Laird Jr
Thursday, October 15•BRAVO 3: A Prospective Randomized Trial of Bivalirudin Versus Heparin in Patients Undergoing Transcatheter Aortic Valve ReplacementThierry Lefevre
•SAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis – One-Year OutcomesHoward C. Herrmann
•RESPECT: A Prospective Randomized Trial of PFO Closure In Patients With Cryptogenic Stroke - Long-Term ResultsJohn D. Carroll
•Evaluation of Initial Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic StenosisTomohiko Taniguchi
•PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic ValvesJohn G. Webb
Receive updates on Twitter: http://twitter.com/TCTConference.
About CRF and TCTThe Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with heart disease through high quality research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. For more than 25 years, TCT has featured major medical research breakthroughs and gathered leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.
For more information, visit www.crf.org and www.tctconference.com.
###
RSS